Skip to content

A Modular Cloud Platform For Fertility Preservation

A Modular CLoud Based Platform To Enhance Fertility Preservation Awareness: Design, Pilot Testing And Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07642531
Enrollment
140
Registered
2026-06-11
Start date
2026-09-02
Completion date
2027-01-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Preservation, Gynecologic Cancers

Keywords

fertility, gynecologic cancer, fertility preservation, mobile application

Brief summary

The research was designed as a randomized controlled study to determine the effectiveness of a modular cloud-based training platform in increasing awareness of fertility preservation. The study aims to develop a free, modular, cloud-based, sustainable digital platform to increase fertility awareness. The platform will provide basic information on fertility preservation methods in plain language to support informed decisions. Content will be based on European Society of Human Reproduction and Embryology (ESHRE) , International Federation of Gynaecology and Obstetrics (FIGO) and Asian Society of Gynecologic Oncology (ASCO) guidelines. The study targets not only cancer patients but also women requesting fertility preservation for medical or social reasons. In the first stage, the platform will be designed with the ADDIE instructional design model (Analysis, Design, Development, Implementation, Evaluation) and content created per international guidelines. In the second stage, the prototype will be pilot-tested and revised. In the third stage, effectiveness will be tested through a randomized controlled trial. Educational modules will be provided to the intervention group, while the control group will receive brochures. The study will include women aged 18-45 with early-stage gynecological cancer (cervix, ovary, tube, endometrium) at Prof. Dr. Cemil Tascioglu City Hospital, untreated. Participants must have Turkish literacy and internet access. Sample size, calculated with G\*Power, is 140 total (70 per group).

Detailed description

This is a randomized controlled experimental study. The research was carried out in the Prof. Dr. Cemil Tascioglu City Hospital.

Interventions

OTHERDeveloping a Modular Cloud-Based Platform to guide decision-making in fertility preservation

In this study, a modular cloud-based platform will be developed to raise awareness about fertility preservation.

Sponsors

Biruni University
Lead SponsorOTHER
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

The study will include women aged 18-45 with early-stage gynecological cancer (cervix, ovary, tube, endometrium) at Prof. Dr. Cemil Tascioglu City Hospital, untreated. Participants must have Turkish literacy and internet access. Sample size, calculated with G\*Power, is 140 total (70 per group). In study, In the intervention group (n = 70), the mobile application will be downloaded and demonstrated to the participants. In the control group (n = 70) will receive only a printed brochure containing the same content as the mobile application.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Women of reproductive age between the ages of 18 and 45, * Diagnosed with early stage cervical cancer, ovarian cancer, tubal cancer and endometrial cancer and whose treatment has not started, * Those who have a smartphone and can use the platform, * Volunteering and giving informed consent, * Turkish literate, * Individuals who do not report mental problems * Do not have children, * Marital status is married or single.

Exclusion criteria

* Neurological disease (e.g., stroke, multiple sclerosis) or cognitive impairment, * Advanced-stage gynecologic cancers, * Failure to complete the follow-up period, * Initiation of oncologic treatment during the study period, * Non-completion or incomplete completion of the data collection instruments, * Non-use of the platform among participants allocated to the intervention group, * History of prior cancer treatment.

Design outcomes

Primary

MeasureTime frameDescription
Awareness rates regarding fertility preservation options among patients in the experimental and control groupsChange from beginning of the study and after 3 weeks of after the mobile application is givenThese data will be obtained through the answers given to the "Awareness status questionnaire for fertility protection".
fertility preservation knowledge scoresChange from beginning of the study and after 3 weeks of after the mobile application is givenThe Fertility Health Knowledge Scale was developed to evaluate individuals' level of knowledge about fertility health; The Turkish validity and reliability study of the scale was conducted. In this study, the knowledge level of the participants regarding fertility/fertility preservation will be evaluated based on the knowledge score using the scale in question.
fertility preservation attitude scoresChange from beginning of the study and after 3 weeks of after the mobile application is givenThe Attitudes Toward Fertility and Childbearing Scale was developed to evaluate the attitudes of women who have not yet become mothers towards fertility and childbearing. The Turkish validity and reliability study of the scale was conducted. In this study, participants' attitude scores (sub-dimensions and total attitude level) towards fertility and childbearing will be evaluated using the scale in question.
Acceptance of fertility preservationChange from beginning of the study and after 3 weeks of after the mobile application is givennumber of patients undergoing fertility preservation procedures

Countries

Turkey (Türkiye)

Contacts

CONTACTNezihe KIZILKAYA BEJI, Professor
nbeji@biruni.edu.tr90+ 0532 502 34 94
CONTACTHuriye Sena Kuruc, MSc
skuruc@biruni.edu.tr90+ 0531 458 13 13
PRINCIPAL_INVESTIGATORNezihe KIZILKAYA BEJI, Professor

Biruni University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026